Study of REXULTI for agitation in Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial is studying how a medication called REXULTI works in patients with Alzheimer's disease who have symptoms like excessive activity, aggression, or mood swings. It aims to see if the drug helps manage these behaviors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alzheimer's disease
- You have symptoms like being overly active, irritable, or showing verbal or physical aggression
- You are willing to take a study medication and follow the trial schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
This trial studies treatment for troubling nighttime restlessness and agitation in people with Alzheimer’s disease. It may help improve sleep and nighttime comfort and reduce nighttime behavior problems.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
This trial studies whether RGn600 can help people with mild to moderate Alzheimer’s disease. You may be able to join if you meet age, test-score, scan, bloodwork, and safety requirements and can attend study visits with a regular caregiver.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.